Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Deep learning tools for advancing drug discovery and development

Open access
Nag, Sagorika, Baidya, Anurag T. K., Mandal, Abhimanyu, Mathew, Alen T., Das, Bhanuranjan, Devi, Bharti, Kumar, Rajnish · 2022 · 3 Biotech

Abstract

A few decades ago, drug discovery and development were limited to a bunch of medicinal chemists working in a lab with enormous amount of testing, validations, and synthetic procedures, all contributing to considerable investments in time and wealth to get one drug out into the clinics. The advancements in computational techniques combined with a boom in multi-omics data led to the development of various bioinformatics/pharmacoinformatics/cheminformatics tools that have helped speed up the drug development process. But with the advent of artificial intelligence (AI), machine learning (ML) and deep learning (DL), the conventional drug discovery process has been further rationalized. Extensive biological data in the form of big data present in various databases across the globe acts as the raw materials for the ML/DL-based approaches and helps in accurate identifications of patterns and models which can be used to identify therapeutically active molecules with much fewer investments on time, workforce and wealth. In this review, we have begun by introducing the general concepts in the drug discovery pipeline, followed by an outline of the fields in the drug discovery process where ML/DL can be utilized. We have also introduced ML and DL along with their applications, various learning methods, and training models used to develop the ML/DL-based algorithms. Furthermore, we have summarized various DL-based tools existing in the public domain with their application in the drug discovery paradigm which includes DL tools for identification of drug targets and drug-target interaction such as DeepCPI, DeepDTA, WideDTA, PADME DeepAffinity, and DeepPocket. Additionally, we have discussed various DL-based models used in protein structure prediction, de novo design of new chemical scaffolds, virtual screening of chemical libraries for hit identification, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, metabolite prediction, clinical trial design, and oral bioavailability prediction. In the end, we have tried to shed light on some of the successful ML/DL-based models used in the drug discovery and development pipeline while also discussing the current challenges and prospects of the application of DL tools in drug discovery and development. We believe that this review will be useful for medicinal and computational chemists searching for DL tools for use in their drug discovery projects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13205-022-03165-8

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 106

  1. Abiodun OI, Jantan A, Omolara AE, Dada KV, Mohamed NA, Arshad H (2018) State-of-the-art in artificial neural network applications: a survey. Heliyon 4(11):e00938 · DOI · Paper page
  2. Abraham A (2005) Artificial neural networks. In: Sydenham PH, Thorn R (eds) Handbook of measuring system design. Wiley, Hoboken, NJ · DOI · Paper page
  3. Alqahtani S (2017) In silico ADME-Tox modeling: progress and prospects. Expert Opin Drug Metab Toxicol 13(11):1147–1158 · DOI · Paper page
  4. Arora K, Bist AS (2020) Artificial intelligence based drug discovery techniques for covid-19 detection. Aptisi Trans Technopreneurship (ATT) 2(2):120–126 · DOI
  5. Aumentado-Armstrong TT, Istrate B, Murgita RA (2015) Algorithmic approaches to protein-protein interaction site prediction. Algorithms Mol Biol 10(1):1–21 · DOI
  6. Bácskay I, Nemes D, Fenyvesi F, Váradi J, Vasvári G, Fehér P, Vecsernyés M, Ujhelyi Z (2018) Role of cytotoxicity experiments in pharmaceutical development. InTech, London · DOI
  7. Bahi M, Batouche M Deep learning for ligand-based virtual screening in drug discovery. In: 2018 3rd international conference on pattern analysis and intelligent systems (PAIS), 2018. IEEE, pp 1–5 · DOI
  8. Batool M, Ahmad B, Choi S (2019) A structure-based drug discovery paradigm. Int J Mol Sci 20(11):2783 · DOI · Paper page
  9. Beck BR, Shin B, Choi Y, Park S, Kang K (2020) Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J 18:784–790 · DOI · Paper page
  10. Bender A, Cortes-Ciriano I (2021) Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data used for AI in drug discovery. Drug Discov Today 26(4):1040–1052 · DOI · Paper page
  11. Brydges R, Dubrowski A, Regehr G (2010) A new concept of unsupervised learning: directed self-guided learning in the health professions. Acad Med 85(10):S49–S55 · DOI
  12. Cereto-Massagué A, Ojeda MJ, Valls C, Mulero M, Garcia-Vallvé S, Pujadas G (2015) Molecular fingerprint similarity search in virtual screening. Methods 71:58–63 · DOI · Paper page
  13. Chan HS, Shan H, Dahoun T, Vogel H, Yuan S (2019) Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci 40(8):592–604 · DOI · Paper page
  14. Chen B, Harrison RF, Papadatos G, Willett P, Wood DJ, Lewell XQ, Greenidge P, Stiefl N (2007) Evaluation of machine-learning methods for ligand-based virtual screening. J Comput Aided Mol Des 21(1):53–62 · DOI
  15. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T (2018a) The rise of deep learning in drug discovery. Drug Discov Today 23(6):1241–1250 · DOI · Paper page
  16. Dara S, Dhamercherla S, Jadav SS, Babu C, Ahsan MJ (2022) Machine learning in drug discovery: a review. Artif Intell Rev 55(3):1947–1999 · DOI · Paper page
  17. de Carvalho TM, Noels E, Wakkee M, Udrea A, Nijsten T (2019) Development of smartphone apps for skin cancer risk assessment: progress and promise. JMIR Dermatol 2(1):e13376 · DOI
  18. Deng H, Jia Y, Zhang Y (2018) Protein structure prediction. Int J Mod Phys B 32(18):1840009 · DOI
  19. Deore AB, Dhumane JR, Wagh R, Sonawane R (2019) The stages of drug discovery and development process. Asian J Pharm Res Dev 7(6):62–67 · DOI · Paper page
  20. Despotovic DTaV (2012) In: Metallurgy—advances in materials and processes, Yogiraj Pardhi. IntechOpen. https://doi.org/10.5772/47850 · doi:10.5772/47850
  21. Díaz Ó, Dalton JA, Giraldo J (2019) Artificial intelligence: a novel approach for drug discovery. Trends Pharmacol Sci 40(8):550–551 · DOI
  22. Ding X, Zhang B (2021) DeepBAR: a fast and exact method for binding free energy computation. J Phys Chem Lett 12(10):2509–2515 · DOI
  23. Ding Y, Tang J, Guo F (2021) Identification of drug-target interactions via multi-view graph regularized link propagation model. Neurocomputing 461:618–631 · DOI
  24. Djoumbou-Feunang Y, Fiamoncini J, Gil-de-la-Fuente A, Greiner R, Manach C, Wishart DS (2019) BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification. J Cheminform 11(1):1–25 · DOI · Paper page
  25. Dridi S (2021) Unsupervised Learning - A Systematic Literature Review. https://doi.org/10.13140/RG.2.2.16963.12323 · doi:10.13140/rg.2.2.16963.12323
  26. Eckert H, Bajorath J (2007) Molecular similarity analysis in virtual screeni ng: foundations, limitations and novel approaches. Drug Discov Today 12(5–6):225–233 · DOI · Paper page
  27. Ekins S (2016) The next era: deep learning in pharmaceutical research. Pharm Res 33(11):2594–2603 · DOI · Paper page
  28. Elbadawi M, Gaisford S, Basit AW (2021) Advanced machine-learning techniques in drug discovery. Drug Discov Today 26(3):769–777 · DOI · Paper page
  29. Feng Q, Dueva E, Cherkasov A, Ester M (2018) Padme: A deep learning-based framework for drug-target interaction prediction. arXiv preprint arXiv:180709741
  30. Flaten HK, St Claire C, Schlager E, Dunnick CA, Dellavalle RP (2018) Growth of mobile applications in dermatology—2017 update. Dermatol Online J 24(2):13–16 · DOI
  31. Fletcher EP, Madabushi R, Sahajwalla CG, Lesko LJ, Huang S-M (2022) The role of the FDA in guiding drug development. In: Huang S-M, Lertora J, Vicini P, Atkinson, A Jr (eds) Atkinson’s principles of clinical pharmacology. Elsevier, pp 681–690 · DOI
  32. Fouad F (2019) The fourth industrial revolution is the AI revolution an academy prospective. Int J Inf 8(5):155–167
  33. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB (2015) Fundamentals of clinical trials. Springer, Cham · DOI · Paper page
  34. Gao K, Nguyen DD, Sresht V, Mathiowetz AM, Tu M, Wei G-W (2020) Are 2D fingerprints still valuable for drug discovery? Phys Chem Chem Phys 22(16):8373–8390 · DOI
  35. Gardner S, Das S, Taylor K (2020) AI enabled precision medicine: patient stratification, drug repurposing and combination therapies. In: Cassidy J, Taylor B (eds) Artificial intelligence in oncology drug discovery and development. IntechOpen · DOI
  36. Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C (2021) Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues. Pharmaceuticals 14(8):738 · DOI
  37. Gentile F, Agrawal V, Hsing M, Ton A-T, Ban F, Norinder U, Gleave ME, Cherkasov A (2020) Deep docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent Sci 6(6):939–949 · DOI · Paper page
  38. Guo Y, Li W, Wang B, Liu H, Zhou D (2019) DeepACLSTM: deep asymmetric convolutional long short-term memory neural models for protein secondary structure prediction. BMC Bioinform 20(1):1–12 · DOI
  39. Gupta N (2013) Artificial neural network. Netw Complex Syst 3(1):24–28
  40. Gurney K (2018) An introduction to neural networks. CRC Press, Boca Raton · doi:10.1201/9781315273570
  41. Hefti FF (2008) Requirements for a lead compound to become a clinical candidate. BMC Neurosci 9(3):1–7
  42. IJzerman AP, Guo D (2019) Drug–target association kinetics in drug discovery. Trends Biochem Sci 44(10):861–871 · DOI
  43. Jimenez-Carretero D, Abrishami V, Fernandez-de-Manuel L, Palacios I, Quílez-Álvarez A, Díez-Sánchez A, Del Pozo MA, Montoya MC (2018) Tox_ (R) CNN: deep learning-based nuclei profiling tool for drug toxicity screening. PLoS Comput Biol 14(11):e1006238 · DOI
  44. Jing Y, Bian Y, Hu Z, Wang L, Xie X-QS (2018a) Deep learning for drug design: an artificial intelligence paradigm for drug discovery in the big data era. AAPS J 20(3):1–10 · DOI · Paper page
  45. Jing Y, Bian Y, Hu Z, Wang L, Xie XQ (2018b) Deep learning for drug design: an artificial intelligence paradigm for drug discovery in the big data era. Aaps j 20(3):58. https://doi.org/10.1208/s12248-018-0210-0 · DOI · Paper page
  46. Karimi M, Wu D, Wang Z, Shen Y (2019) DeepAffinity: interpretable deep learning of compound–protein affinity through unified recurrent and convolutional neural networks. Bioinformatics 35(18):3329–3338 · DOI · Paper page
  47. Kerns EH, Di L (2003) Pharmaceutical profiling in drug discovery. Drug Discov Today 8(7):316–323 · DOI · Paper page
  48. Khan A, Kaushik AC, Ali SS, Ahmad N, Wei D-Q (2019) Deep-learning-based target screening and similarity search for the predicted inhibitors of the pathways in Parkinson’s disease. RSC Adv 9(18):10326–10339 · DOI
  49. Kinch LN, Pei J, Kryshtafovych A, Schaeffer RD, Grishin NV (2021) Topology evaluation of models for difficult targets in the 14th round of the critical assessment of protein structure prediction (CASP14). Proteins Struct Funct Bioinform 89(12):1673–1686 · DOI
  50. Korshunova M, Ginsburg B, Tropsha A, Isayev O (2021) OpenChem: a deep learning toolkit for computational chemistry and drug design. J Chem Inf Model 61(1):7–13 · DOI
  51. Kotsiantis SB, Zaharakis I, Pintelas P (2007) Supervised machine learning: a review of classification techniques. Emerg Artif Intell Appl Comput Eng 160(1):3–24
  52. Krittanawong C, Johnson KW, Tang WW (2019) How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology. Future Med 16(2):87–92
  53. Lai J, Li X, Wang Y, Yin S, Zhou J, Liu Z (2020) AIScaffold: a web-based tool for scaffold diversification using deep learning. J Chem Inf Model 61(1):1–6 · DOI
  54. Larranaga P, Calvo B, Santana R, Bielza C, Galdiano J, Inza I, Lozano JA, Armananzas R, Santafé G, Pérez A (2006) Machine learning in bioinformatics. Brief Bioinform 7(1):86–112 · DOI · Paper page
  55. Lavecchia A (2015) Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today 20(3):318–331 · DOI · Paper page
  56. Lavecchia A (2019) Deep learning in drug discovery: opportunities, challenges and future prospects. Drug Discov Today 24(10):2017–2032 · DOI · Paper page
  57. Li Y, Hu J, Wang Y, Zhou J, Zhang L, Liu Z (2019) Deepscaffold: a comprehensive tool for scaffold-based de novo drug discovery using deep learning. J Chem Inf Model 60(1):77–91 · DOI
  58. Li Q, Shah S (2017) Structure-based virtual screening. In: Wu CH, Arighi CN, Ross KE (eds) Protein bioinformatics. Springer, pp 111–124 · DOI
  59. Lin J, Sahakian DC, De Morais S, Xu JJ, Polzer RJ, Winter SM (2003) The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 3(10):1125–1154 · DOI · Paper page
  60. Lionta E, Spyrou G, Vassilatis D, Cournia Z (2014) Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem 14(16):1923–1938 · DOI · Paper page
  61. Liu Z, Du J, Fang J, Yin Y, Xu G, Xie L (2019a) DeepScreening: a deep learning-based screening web server for accelerating drug discovery. Database. https://doi.org/10.1093/database/baz104 · DOI
  62. Liu Z, Du J, Fang J, Yin Y, Xu G, Xie L (2019b) DeepScreening: a deep learning-based screening web server for accelerating drug discovery. Database J Biol Databases Cur. https://doi.org/10.1093/database/baz104 · DOI
  63. Luo Y, Zhao X, Zhou J, Yang J, Zhang Y, Kuang W, Peng J, Chen L, Zeng J (2017) A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun 8(1):1–13 · DOI · Paper page
  64. Maltarollo VG, Gertrudes JC, Oliveira PR, Honorio KM (2015) Applying machine learning techniques for ADME-Tox prediction: a review. Expert Opin Drug Metab Toxicol 11(2):259–271 · DOI · Paper page
  65. Maragakis P, Nisonoff H, Cole B, Shaw DE (2020) A deep-learning view of chemical space designed to facilitate drug discovery. J Chem Inf Model 60(10):4487–4496 · DOI
  66. Mauser H, Guba W (2008) Recent developments in de novo design and scaffold hopping. Curr Opin Drug Discov Devel 11(3):365–374
  67. Min S, Lee B, Yoon S (2017) Deep learning in bioinformatics. Brief Bioinform 18(5):851–869
  68. Mohs RC, Greig NH (2017) Drug discovery and development: role of basic biological research. Alzheimer’s Dementia Transl Res Clin Interv 3(4):651–657 · DOI · Paper page
  69. Morris GM, Lim-Wilby M (2008) Molecular docking. In: Kukol A (eds) Molecular modeling of proteins. Springer, pp 365–382 · DOI · Paper page
  70. Muegge I, Mukherjee P (2016) An overview of molecular fingerprint similarity search in virtual screening. Expert Opin Drug Discov 11(2):137–148 · DOI · Paper page
  71. Musella S, Verna G, Fasano A, Di Micco S (2021) New perspectives on machine learning in drug discovery. Curr Med Chem 28(32):6704–6728 · doi:10.2174/0929867327666201111144048
  72. Nayak A, Dutta K Impacts of machine learning and artificial intelligence on mankind. In: 2017 international conference on intelligent computing and control (I2C2), 2017. IEEE, pp 1–3 · DOI
  73. Olivecrona M, Blaschke T, Engkvist O, Chen H (2017) Molecular de-novo design through deep reinforcement learning. J Cheminform 9(1):1–14 · DOI · Paper page
  74. Ongsulee P (2017) Artificial intelligence, machine learning and deep learning. In: 2017 15th international conference on ICT and knowledge engineering (ICT&KE), 2017. IEEE, pp 1–6 · DOI · Paper page
  75. Öztürk H, Özgür A, Ozkirimli E (2018) DeepDTA: deep drug–target binding affinity prediction. Bioinformatics 34(17):i821–i829 · DOI · Paper page
  76. Öztürk H, Ozkirimli E, Özgür A (2019) WideDTA: prediction of drug-target binding affinity. arXiv preprint arXiv:190204166 · DOI · Paper page
  77. Parasa NA, Namgiri JV, Mohanty SN, Dash JK (2021) Introduction to unsupervised learning in bioinformatics. In: Data analytics in bioinformatics: a machine learning perspective. Wiley-Scrivener, Hoboken, NJ, pp 35–49 · DOI
  78. Pathania A, Kumar R, Sandhir R (2021) Hydroxytyrosol as anti-parkinsonian molecule: Assessment using in-silico and MPTP-induced Parkinson’s disease model. Biomed Pharmacother 139:111525 · doi:10.1016/j.biopha.2021.111525
  79. Perron Q, Mirguet O, Tajmouati H, Skiredj A, Rojas A, Gohier A, Ducrot P, Bourguignon M-P, Sansilvestri-Morel P, Do Huu N, Gellibert F, Gaston-Mathé Y (2022) Deep generative models for ligand-based de novo design applied to multi-parametric optimization. J Comput Chem 43(10):692–703 · DOI
  80. Piantadosi S (2017) Clinical trials: a methodologic perspective. Wiley, New York
  81. Popova M, Isayev O, Tropsha A (2018) Deep reinforcement learning for de novo drug design. Sci Adv 4(7):eaap7885 · DOI · Paper page
  82. Puri M, Solanki A, Padawer T, Tipparaju SM, Moreno WA, Pathak Y (2016) Introduction to artificial neural network (ANN) as a predictive tool for drug design, discovery, delivery, and disposition: Basic concepts and modeling. In: Puri M, Pathak Y, Sutariya V, Tipparaju S, Moreno W (eds) Artificial neural network for drug design, delivery and disposition. Elsevier, pp 3–13 · DOI
  83. Rayhan F, Ahmed S, Mousavian Z, Farid DM, Shatabda S (2020) FRnet-DTI: deep convolutional neural network for drug-target interaction prediction. Heliyon 6(3):e03444 · DOI
  84. Rayhan F, Ahmed S, Mousavian Z, Farid DM, Shatabda S (2018) FRnet-DTI: convolutional neural networks for drug-target interaction. arXiv preprint arXiv:180607174 7 · DOI
  85. Rezaei MA, Li Y, Wu D, Li X, Li C (2020) Deep learning in drug design: protein–ligand binding affinity prediction. IEEE/ACM Trans Comput Biol Bioinform. https://doi.org/10.1109/TCBB.2020.3046945 · DOI
  86. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (london, England) 395(10223):e30 · DOI · Paper page
  87. Ripphausen P, Nisius B, Bajorath J (2011) State-of-the-art in ligand-based virtual screening. Drug Discov Today 16(9–10):372–376 · DOI · Paper page
  88. Sahoo P, Roy I, Wang Z, Mi F, Yu L, Balasubramani P, Khan L, Stoddart JF (2020) MultiCon: a semi-supervised approach for predicting drug function from chemical structure analysis. J Chem Inf Model 60(12):5995–6006 · DOI
  89. Schneider G, Fechner U (2005) Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 4(8):649–663 · DOI · Paper page
  90. Schneider P, Schneider G (2016) De novo design at the edge of chaos: miniperspective. J Med Chem 59(9):4077–4086 · DOI · Paper page
  91. Shen C, Ding J, Wang Z, Cao D, Ding X, Hou T (2020) From machine learning to deep learning: advances in scoring functions for protein–ligand docking. Wiley Interdiscip Rev Comput Mol Sci 10(1):e1429 · DOI · Paper page
  92. Shetty P, Singh S (2021) Hierarchical clustering: a survey. IJAR 7(4):178–181
  93. Smith JS, Roitberg AE, Isayev O (2018) Transforming computational drug discovery with machine learning and AI, vol 9. ACS Publications, New York
  94. Stephenson N, Shane E, Chase J, Rowland J, Ries D, Justice N, Zhang J, Chan L, Cao R (2019) Survey of machine learning techniques in drug discovery. Curr Drug Metab 20(3):185–193 · DOI · Paper page
  95. Tavallali P, Tavallali P, Singhal M (2021) K-means tree: an optimal clustering tree for unsupervised learning. J Supercomput 77(5):5239–5266 · DOI
  96. Thafar M, Raies AB, Albaradei S, Essack M, Bajic VB (2019a) Comparison study of computational prediction tools for drug-target binding affinities. Front Chem 7:782. https://doi.org/10.3389/fchem.2019.00782 · DOI
  97. Walczak S (2018) The role of artificial intelligence in clinical decision support systems and a classification framework. Int J Comput Clin Pract (IJCCP) 3(2):31–47 · DOI
  98. Wang D, Liu W, Shen Z, Jiang L, Wang J, Li S, Li H (2020) Deep learning based drug metabolites prediction. Front Pharmacol 10:1586 · DOI
  99. Wang S-C (2003) Artificial neural network. In: Wang S-C (eds) Interdisciplinary computing in java programming. Springer, pp 81–100 · DOI · Paper page
  100. Wei G-W (2019) Protein structure prediction beyond AlphaFold. Nat Mach Intell 1(8):336–337 · DOI
  101. Wildey MJ, Haunso A, Tudor M, Webb M, Connick JH (2017) High-throughput screening. Annu Rep Med Chem 50:149–195
  102. Woo M (2019a) An AI boost for clinical trials. Nature 573(7775):S100-s102. https://doi.org/10.1038/d41586-019-02871-3 · DOI
  103. Wu D, Huang Q, Zhang Y, Zhang Q, Liu Q, Gao J, Cao Z, Zhu R (2012) Screening of selective histone deacetylase inhibitors by proteochemometric modeling. BMC Bioinform 13(1):1–10 · DOI
  104. Yasuo N, Sekijima M (2017) Development of postprocessing method of protein-ligand docking using interaction fingerprint. Biophys J 112(3):452a · doi:10.1016/j.bpj.2016.11.2423
  105. Yasuo N, Sekijima M (2019) Improved method of structure-based virtual screening via interaction-energy-based learning. J Chem Inf Model 59(3):1050–1061 · DOI
  106. Zhang HH (2014) Supervised Learning. In: Wiley StatsRef: Statistics Reference Online. Wiley, pp 1–17 · DOI

Cited by

See all 174

Metadata

Authors
Nag, S., Baidya, A. T. K., Mandal, A., Mathew, A. T., Das, B., Devi, B., & Kumar, R.
Venue
3 Biotech
Published
2022-04-09
Volume
12
Issue
5
Pages
110-110
ISSN
  • 2190-572X (ISSN-L)
  • 2190-5738
OpenAlex
W4224279656
Cited by
174
References
25
FWCI
19.13
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Science and Engineering Research Board (SRG/2021/000415, MTR/2021/000317)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deep learning tools for advancing drug discovery and development. https://app.cochat.ai/papers/10.1007/s13205-022-03165-8
The paper
Nag, S., Baidya, A. T. K., Mandal, A., Mathew, A. T., Das, B., Devi, B., & Kumar, R. (2022). Deep learning tools for advancing drug discovery and development. 3 Biotech. https://doi.org/10.1007/s13205-022-03165-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.